Genmab A/S (GMAB) Scheduled to Post Quarterly Earnings on Thursday

Genmab A/S (NASDAQ:GMAB) is set to release its earnings data before the market opens on Thursday, May 2nd. Analysts expect Genmab A/S to post earnings of $0.16 per share for the quarter. Genmab A/S has set its FY 2024 guidance at EPS.Individual interested in participating in the company’s earnings conference call can do so using this link.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. On average, analysts expect Genmab A/S to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Genmab A/S Price Performance

GMAB traded down $0.45 during trading on Tuesday, hitting $28.12. The company’s stock had a trading volume of 266,100 shares, compared to its average volume of 578,592. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.72. The stock has a market cap of $18.59 billion, a PE ratio of 29.76, a PEG ratio of 2.02 and a beta of 0.98. The firm’s 50 day moving average price is $29.44 and its 200-day moving average price is $29.97.

Analysts Set New Price Targets

A number of research firms have recently commented on GMAB. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Truist Financial reiterated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup cut Genmab A/S from a “neutral” rating to a “sell” rating in a report on Monday, January 22nd. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Tuesday. Finally, BMO Capital Markets raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of “Hold” and an average target price of $48.50.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.